In plain English
Merck & Co. develops and sells prescription medicines and vaccines, focusing on oncology, cardiovascular, and rare disease treatments. The…
Equity · NYSE · USD
MRK
Merck & Co Inc
$147.96
Today
−$2.95-1.95%
vs previous close
Quote
- Open
- $151.31
- High
- $152.01
- Low
- $147.83
- Prev close
- $150.91
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Size
- Large-cap
- Market cap
- $368.8B
- Shares out
- 2.47B
- Country
- US
- IPO
- Jan 1, 1941
- Exchange
- NYSE
- Website
- merck.com
- Next earnings
- 2026-10-29 · EPS est. 2.22
Themes
Price chart Pro
Loading chart…
Loading chart…
Company briefing
What MRK is
Plain English context — why the name shows up in the news, and what to watch next. Not a tip.
Latest on this name
Insights & deeper context
24 recent cards — open any for the full deeper dive.
Merck Says FDA Approves Update To US Product Label For WINREVAIR For Injection, 45mg, 60mg, Based On The Phase 3 HYPERION Trial
In brief
Merck’s FDA label approval for WINREVAIR in newly diagnosed PAH patients could broaden its use and improve patient outcomes.
Merck's Subcutaneous KEYTRUDA QLEX Approved In Japan For All Existing KEYTRUDA Indications
In brief
Merck’s new subcutaneous KEYTRUDA QLEX gets Japanese approval, enabling one‑minute injections for all current indications.
Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer
In brief
Merck’s Keytruda plus Padcev combo is poised for EU approval, broadening treatment options for bladder‑cancer patients and boosting Merck’s oncology portfolio.
EU CHMP Adopts Positive Opinion Recommending Approval Of KEYTRUDA, Merck’s Anti-PD-1 Therapy, In Combination With Padcev As Neoadjuvant Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer
In brief
EU regulators are poised to approve the first PD‑1 inhibitor plus antibody‑drug conjugate combo for bladder cancer, based on strong Phase 3 data.
Moderna Stock More Than Doubled in a Month. Now Comes the Hard Part
In brief
Moderna’s Phase 3 melanoma win validates its mRNA cancer platform, but the real test lies in scaling manufacturing, securing approvals, and expanding to other cancers.
Novo Nordisk, Anthropic Team Up For AI Drug Research
In brief
Novo Nordisk’s new AI partnership with Anthropic could accelerate drug discovery and strengthen its competitive position in biopharma.
Perspective Therapeutics Enters Clinical Trial Collaboration With Merck To Combine Its PSV359 With Keytruda Under An Amendment To Ongoing Phase 1/2A Study Of PSV359 In Patients With Certain Types Of Non-Small Cell Lung Cancer And Colorectal Cancer
In brief
Perspective and Merck are teaming up to test a promising combo of radiopharmaceutical and immunotherapy in solid tumors, potentially opening a new therapeutic avenue.
Congresswoman Bets on Elon Musk, Warren Buffett: Here’s the Latest Stock Transactions
In brief
Salazar’s August trades show a bullish stance on Musk’s SpaceX, Buffett’s Berkshire, and biotech leaders, potentially guiding retail investors and adding pressure on those stocks.
Recent Filing Shows That Rep. Maria Elvira Salazar Bought Over $34K Worth of Merck & Co Stock
In brief
Salazar’s MRK purchase signals a modest bullish stance, but the trade’s size limits immediate market impact.
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
In brief
Positive Phase 3 results for a personalized mRNA cancer vaccine could ignite a new biotech boom beyond obesity drugs, boosting genomics and precision‑medicine ETFs.
Measles Kills 2 in Pennsylvania: What Do Prediction Markets Say About the Disease?
In brief
Measles deaths in Pennsylvania mark a worrying resurgence, with markets pricing a sharp rise in cases that could boost vaccine sales but strain public health efforts.
Moderna Stock Edges Higher Tuesday: What's Happening?
In brief
Moderna’s stock gains are driven by a breakthrough melanoma trial and analyst upgrades that boost its oncology outlook.
Court Rejects Merck’s Challenge to Medicare Drug Price Negotiation Program
In brief
Merck’s challenge to the IRA’s drug‑price negotiation program was rejected, affirming federal pricing authority and exposing the company to lower prices or hefty penalties.
What’s Going On With Tempus AI Stock on Monday?
In brief
TEM’s recent pullback reflects a re‑pricing of its momentum‑driven rally, with FDA clearance adding a new product but analyst sentiment remaining split.
Dr. Oz Says The MMR Vaccine Is Not 'Lethal' as Trump Administration Faces Questions Over Vaccine Policy
In brief
Oz’s statement counters Trump’s claim that MMR is lethal, but the new policy could still shift demand toward separate shots, impacting vaccine manufacturers.
If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now
In brief
Moderna’s Phase 3 cancer vaccine win has revived the stock, underscoring the company’s shift from pandemic focus to broader mRNA therapeutics.
COVID-19 Made Moderna Famous: Cancer Could Define Its Future
In brief
Moderna’s Phase 3 melanoma win could be the catalyst that turns its mRNA platform into a sustainable oncology business, redefining its future beyond COVID‑19.
QUICK SPARK: Moderna Stock Drops 25%, Eyes Worst Day in Company's History
In brief
Moderna’s record rally was quickly erased by a 25.69% slide, reflecting the high stakes of its first Phase 3 mRNA cancer therapy and the weight of its short‑interest profile.
Why Iovance Biotherapeutics Stock Hit 52-Week High
In brief
Iovance’s 52‑week high is fueled by industry momentum from Moderna and Merck’s breakthrough data, not by new company announcements, but by the broader confidence in individualized cancer therapies.
Moderna's Intismeran Close to Keytruda Style Oncology Opportunity: Analyst
In brief
Intismeran’s strong interim data lift its approval odds and open a Keytruda‑style revenue stream, but investors remain cautious about its broader oncology potential.
Pharma Bro Admits 'Playing Around' With MRNA Short At $80 Before it Exploded 177% Following Cancer Vax Trials— ‘I Bet You a Bunch of People Got Fired’
In brief
Moderna’s cancer‑vaccine win triggered a 177% stock jump that caught many traders off‑balance, exposing gaps in biotech positioning.
This Merck Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
In brief
Analyst upgrades across the board suggest a bullish tilt for PGR, MRK, EPR, ETSY, and ADI, with price targets climbing to $250, $179, $70, $105, and $425 respectively.
Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Fall as Trump Launches ‘Operation Economic Fury’ on Iran— BULL, WMT, MRK Stock in Focus (UPDATED)
In brief
Geopolitical tension over Iran and a likely Fed rate hike pushed markets lower, but economic data and sector moves keep volatility high.
Why Is Tempus AI Stock Gaining Thursday?
In brief
Positive melanoma trial results are lifting Tempus AI shares as investors weigh the strategic value of its planned Personalis acquisition.
Filings & reports
SEC and filing-linked cards
No filings tagged yet
Filing-linked cards for MRK will show up here when available.
Indexes like the S&P 500 are shown via liquid ETFs (e.g. SPY). Company profile and quotes use live market data when available.